Oncothyreon Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ONTY 3.70 +0.08 (2.21%)
price chart
Takeways from ASCO 2015: Innate Pharma SA, Oncothyreon Inc (USA), and ...
Oncothyreon Inc (USA) (NASDAQ:ONTY) continues to be the biggest benefactor of ASCO this year, now up over 200% since investors had a first glimpse at abstracts from the conference.
Oncothyreon Rating Reiterated by HC Wainright (ONTY)  Dakota Financial News
Why Shares of Oncothyreon Inc. Shot Up Today  Motley Fool
Here's Why Oncothyreon Inc (USA) Shares Are Fully Valued: Cantor
Oncothyreon Inc (USA) (NASDAQ:ONTY) shares have taken off, adding 24.56% to trade at $4.26, after the biotechnology company presented positive study data for its breast cancer treatment at the American Society of Clinical Oncology 2015 meeting.
HC Wainwright Offers Updates on Oncothyreon Inc (USA) (ONTY), Ariad ...
The American Association of Clinical Oncology conference is wrapping up in Chicago. The three day conference brings together thousands of oncology professionals and pharmaceutical companies to share research and new best practices.
Oncothyreon Inc (USA) (NASDAQ:ONTY) a Buy: Jefferies
In a research note issued to investors, Biren Amin at Jefferies Reiterated their Buy rating on Oncothyreon Inc (USA) (NASDAQONTY).
Update: Oncothyreon Inc. Short Interest Increases by 59.7%  Money Flow Index
Pre-Market News Report on: Yelp (NYSE:YELP), Boeing (NYSE:BA ...  wsnewspublishers
Biotech Beat: Oncothyreon Inc (USA), Innate Pharma SA, Regeneron ...
ASCO came to a close early this week, and Oncothyreon Inc (USA) (NASDAQ:ONTY) was this year's undisputed winner among biotech stocks, gaining 185% between May 13 (when abstracts from the conference were released) and the end of this week.
Biotech Stocks with Optimistic Trend - Halozyme Therapeutics, Inc. (NASDAQ ...
Oncothyreon Inc (USA) (NASDAQ:ONTY) advanced +6.40% to finish last trading session at $3.74. The company, on May 30, 2015, reported the presentation of positive data from the company's ongoing trials of ONT-380, an orally active, reversible and ...
Oncothyreon Inc. (NASDAQ:ONTY) Analyst Rating Update  Money Flow Index
Will Oncothyreon Inc. (NASDAQ:ONTY) Surprise This Quarter?  Investor Newswire
Stocks starting to signal a sell: Oncothyreon Inc (USA) (NASDAQ:ONTY ...
Technical analysis indicators such as the Relative Strength Index (RSI), a popular oscillator developed by Welles Wilder, Jr., can be used as watch signals for stocks, providing traders a heads up that although things appear normal, possible changes ...
Investors Dumping 3 Biotech Stocks - Neuralstem, Inc. (NYSEMKT:CUR ...
Oncothyreon Inc (USA) (NASDAQ:ONTY) dropped -9.87% to finish last trading session at $3.52. The company, on May 30, 2015, reported the presentation of positive data from the company's ongoing trials of ONT-380, an orally active, reversible and ...
Today's Best Biotech Stocks: Oncothyreon Inc (USA) (NASDAQ:ONTY), Exelixis ...
Oncothyreon Inc (USA) (NASDAQ:ONTY) grew more than 50% in pre-market trading on Monday after declaring that the experimental breast cancer drug ONT-380 was effective and different from other therapies used to treat women with HER2-positive ...
Biotech Stocks you should dump - Oncothyreon Inc (USA) (NASDAQ:ONTY ...
Oncothyreon Inc (USA) (NASDAQ:ONTY) fell -1.51% to close last trading session at $3.92. The company, on May 30, 2015, declared the presentation of positive data from the company's ongoing trials of ONT-380, an orally active, reversible and selective ...